Arch Biopartners Inc (Arch), recently announced that its drug candidate AB569, which is being developed as treatment for pulmonary Pseudomonas…
Articles by Daniela Semedo, PhD
ProQR Therapeutics, a Leiden, NL based biotech company focused on development of drugs to treat severe genetic disorders, recently…
In a special article published in the journal Mediators of Inflammation, a team of researchers led by…
Children’s Healthcare of Atlanta, Emory University, and Georgia Tech were recently awarded a grant by The Cystic Fibrosis Foundation to…
ManRos Therapeutics SA and Cyclacel Ltd, an exclusively owned subsidiary of Cyclacel Pharmaceuticals, Inc., recently announced a partnership,…
ProQR Therapeutics N.V. a company developing RNA medicines for the treatment of severe diseases including cystic fibrosis, recently announced that…
Laurent Pharmaceuticals Inc., a Montréal-based private biopharmaceutical company currently developing a clinical stage lipid modulator (LAU-7b) designed to…
Galapagos NV, a clinical-stage biotechnology company, recently delivered a joint presentation with AbbVie during the 38th annual conference of the…
Vertex Pharmaceuticals Incorporated  and Parion Sciences recently announced a joint collaboration for the development of investigational epithelial sodium channel…
Denmark-based Serendex Pharmaceuticals, a company developing drugs to treat severe respiratory conditions, recently announced the initiation of a Phase…